Clinical Trials Directory

Trials / Completed

CompletedNCT01119625

Immunological Persistence After Priming With GSK1024850A Vaccine and Safety& Immunogenicity After Booster Dose

Evaluation of Immunological Persistence Following 3-dose Priming With GSK Biologicals' 10-valent Pneumococcal Conjugate Vaccine in Study NCT00808444 and Safety and Immunogenicity Following a Booster Dose of the Same Vaccine

Status
Completed
Phase
Phase 3
Study type
Interventional
Enrollment
238 (actual)
Sponsor
GlaxoSmithKline · Industry
Sex
All
Age
18 Months – 21 Months
Healthy volunteers
Accepted

Summary

This primary purpose of this study is the evaluation of the immunological persistence following completion of the 3-dose primary vaccination course with either a clinical or a commercial lot of pneumococcal conjugate vaccine GSK1024850A in study NCT00808444. In addition, the study will also assess the safety, reactogenicity and immunogenicity of a fourth dose of pneumococcal conjugate vaccine GSK1024850A (commercial lot) when co-administered with Infanrix-IPV/Hib at 18-21 months of age in children primed in study NCT00808444. The primary vaccination study was conducted in Malaysia and Singapore. The booster vaccination study will not be performed in Malaysia since the pneumococcal conjugate vaccine GSK1024850A has been registered in September 2009. However, subjects in Malaysia will be offered a booster dose of the commercial pneumococcal conjugate vaccine licensed in Malaysia and Infanrix-IPV/Hib vaccine during the second year of life according to the nationally recommended regimen. Administration of the booster dose will be outside the set-up of a clinical trial. Hence no data will be collected, no blood samples will be taken in Malaysia.

Conditions

Interventions

TypeNameDescription
BIOLOGICALPneumococcal vaccine GSK1024850AIntramuscular injection, one dose
BIOLOGICALInfanrix-IPV/HibIntramuscular injection, one dose

Timeline

Start date
2010-07-12
Primary completion
2011-02-17
Completion
2011-02-17
First posted
2010-05-07
Last updated
2018-09-20
Results posted
2012-03-22

Locations

3 sites across 1 country: Singapore

Source: ClinicalTrials.gov record NCT01119625. Inclusion in this directory is not an endorsement.

Immunological Persistence After Priming With GSK1024850A Vaccine and Safety& Immunogenicity After Booster Dose (NCT01119625) · Clinical Trials Directory